Topic: clinical trial data
Novocure wants to bring the electric field device to market in mesothelioma via the rarely used humanitarian device exemption.
The seroclearance gives a boost to Arrowhead as it plots a path back from safety concerns that derailed ARC-520 in 2016.
The biotech painted data from the trial as positive, but the outside world took a different view, sending Selecta’s stock down by more than 20%.
The trial's size and AnaptysBio’s analysis of the data leave scope for questions about the results and their implications for the anti-IL-33 antibody.
The results come from a small, exploratory study Reata initiated after wrapping up a trial of the drug in its primary indication.
The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months.
Median PFS is still ticking up in the trial of the CD19 antibody, adding weight to MorphoSys’ claims MOR208 can hold its own against CAR-T therapies.
Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.
The small trial linked antisense drug RG6042 to a 40% drop in levels of the mutant protein that drives the neurodegenerative disease.
The study detected a statistically significant desensitization to milk among a subgroup, although the overall data set leaves questions unanswered.